Homepage Top Section2

Entresto (sacubitril/valsartan) is intended for treating symptomatic chronic heart failure with left ventricular systolic dysfunction in patients who are aged from 1 to <18 years. Novartis global head

A tumour infiltrating lymphocyte (TIL) therapy,  lifileucel is designed to treat patients with advanced (unresectable or metastatic) melanoma who advanced  on or after prior anti-PD-1/L1 therapy and targeted therapy.

Under the deal terms, Macomics will be responsible for identifying and characterising the antibody candidates against a new target leveraging its Enigmac macrophage drug discovery platform. Ono Pharmaceutical

PBP1510 will mainly act on a tumour-specific protein called pancreatic adenocarcinoma upregulated factor (PAUF), which is overexpressed in most pancreatic cancer patients. PAUF overexpression is said to advance

Earlier, ARO-APOC3 received Orphan Drug designation from the FDA and the European Union. ARO-APOC3 is the firm’s investigational RNAi therapeutic targeting apolipoprotein C-III (APOC3). It is being developed

The oral androgen receptor inhibitor (ARi) darolutamide already received approval in China to treat non-metastatic castration-resistant prostate cancer (nmCRPC) patients at high risk of developing metastatic disease. The

With this approval, the firm intends to introduce Xerava in the Chinese market in the third quarter of this year. Xerava is a new fully synthetic, broad-spectrum, fluorocycline

The Series A round was co-led by Novartis Venture Fund and Sofinnova Partners and has seen participation from Pfizer Ventures, Mission BioCapital, Gimv, Pureos, Bristol Myers Squibb, Eli

If given approval, Nucala will become the first targeted anti-Interleukin-5 (IL-5) treatment in the country for adult and adolescent patients with SEA. A first-in-class monoclonal antibody to target